Analyst Price Targets — IMUX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 16, 2026 8:19 pm | — | Stifel Nicolaus | $2.50 | $1.00 | TheFly | Immunic initiated with a Buy at Stifel |
| October 21, 2022 3:14 pm | Market Perform | Leerink Partners | $5.00 | $2.09 | Benzinga | Analyst Downgrades Immunic After Lack of Details Drive Uncertainty |
Latest News for IMUX
Stifel on Thursday initiated coverage on Immunic Inc. (NASDAQ: IMUX), a late-stage biotechnology company developing oral therapies for neurologic and gastrointestinal diseases.
NEW YORK, April 9, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following scientific and medical conferences in April: April 14-16: 8th Annual Neuroimmunology Drug Development Summit. Hella Kohlhof, Ph.D.
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said it will participate in two April conferences. At the Neuroimmunology Drug Development Summit (Apr. 14–16, Boston),...
11:05am: 'Wait and see' Axel Rudolph, chief technical analyst at IG, notes that traders are largely adopting a wait‑and‑see approach as Trump’s deadline for...
NEW YORK, April 1, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on March 27, 2026, informing the company that it has regained compliance with the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMUX.
U.S. House Trading
No House trades found for IMUX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.